Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furazolidone

FDA-approved product (tablet, oral), marketed as Furoxone.

Registered studies
49
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furazolidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Furazolidone. Its therapeutic class is shown instead.

WHO therapeutic group
Other antiinfectives and antiseptics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC G01AX06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis91.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Furazolidone in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furazolidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study

    NCT07455448 · start 2026-03-01

    Registered record
    Registry ID
    NCT07455448
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    Antimicrobial susceptibility testing
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2026-03-01
    Completion
    2026-03-25
    Enrolment
    7,227

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    InterventionAntimicrobial susceptibility testing
    PhaseNot recorded
    Registry statusCompleted

  • Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

    NCT07139366 · start 2025-10-28

    Registered record
    Registry ID
    NCT07139366
    Conditions
    Gastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer; Peptic Ulcer
    Interventions
    Bismuth; Esomeprazole; Tetracycline; Furazolidone; Saccharomyces Boulardii Oral Powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-28
    Completion
    2026-09
    Enrolment
    1,248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer +1 more
    InterventionBismuth; Esomeprazole; Tetracycline; Furazolidone +1 more
    PhasePhase 4
    Registry statusRecruiting

  • The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

    NCT06777732 · start 2025-03

    Registered record
    Registry ID
    NCT06777732
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Keverprazan; Amoxicillin; Furazolidone; Colloidal Bismuth Pectin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2025-03
    Completion
    2026-01
    Enrolment
    672

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionKeverprazan; Amoxicillin; Furazolidone; Colloidal Bismuth Pectin
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment

    NCT06760065 · start 2025-01-15

    Registered record
    Registry ID
    NCT06760065
    Conditions
    Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education
    Interventions
    Keverprazan Hydrochloride tablets + high dose amoxicillin; Susceptibility-Guided Quadruple Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-01-15
    Completion
    2027-12-31
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education
    InterventionKeverprazan Hydrochloride tablets + high dose amoxicillin; Susceptibility-Guided Quadruple Therapy
    PhasePhase 3
    Registry statusNot yet recruiting

  • Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

    NCT06340334 · start 2024-03-31

    Registered record
    Registry ID
    NCT06340334
    Conditions
    Helicobacter Pylori Infection; Tegoprazan; Furazolidone
    Interventions
    Tegoprazan-amoxicillin dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-03-31
    Completion
    2025-09-10
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Tegoprazan; Furazolidone
    InterventionTegoprazan-amoxicillin dual therapy
    PhaseNot applicable
    Registry statusCompleted

  • Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

    NCT06168214 · start 2023-09-04

    Registered record
    Registry ID
    NCT06168214
    Conditions
    the Eradication Rates of Helicobacter Pylori
    Interventions
    Rabeprazloe+bismuth+amoxicillin+clarithromycin; Vonoprazan+amoxicillin+clarithromycin 14 days; Vonoprazan+amoxicillin+clarithromycin 7 days; Vonoprazan+tetracycline+furazolidone 14 days; Vonoprazan+tetracycline+furazolidone 7 days; Vonoprazan+amoxicillin+furazolidone 7 days; Vonoprazan+amoxicillin+tetracycline 14 days; Vonoprazan+amoxicillin 7 days; Vonoprazan+amoxicillin 14 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-09-04
    Completion
    2024-12-25
    Enrolment
    1,404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Conditionthe Eradication Rates of Helicobacter Pylori
    InterventionRabeprazloe+bismuth+amoxicillin+clarithromycin; Vonoprazan+amoxicillin+clarithromycin 14 days; Vonoprazan+amoxicillin+clarithromycin 7 days; Vonoprazan+tetracycline+furazolidone 14 days +5 more
    PhasePhase 4
    Registry statusUnknown

  • Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

    NCT06168084 · start 2023-06-06

    Registered record
    Registry ID
    NCT06168084
    Conditions
    Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
    Interventions
    Vonoprazan; amoxicillin; Bismuth; Esomeprazole; Tetracycline; Furazolidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-06-06
    Completion
    2024-08-30
    Enrolment
    688

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
    InterventionVonoprazan; amoxicillin; Bismuth; Esomeprazole +2 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

    NCT05718609 · start 2023-03-01

    Registered record
    Registry ID
    NCT05718609
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Rabeprazole; Colloidal Bismuth Pectin Granules; Amoxicillin; Furazolidone; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-03-01
    Completion
    2024-06-30
    Enrolment
    855

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionRabeprazole; Colloidal Bismuth Pectin Granules; Amoxicillin; Furazolidone +1 more
    PhasePhase 4
    Registry statusUnknown

  • Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine

    NCT05586464 · start 2022-11-01

    Registered record
    Registry ID
    NCT05586464
    Conditions
    Helicobacter Pylori Infection; Traditional Chinese Medicine; Eradication
    Interventions
    Ban xia xie xin Decoction and bismuth quadruplicate group; Bismuth quadruplicate group
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2024-09-30
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Traditional Chinese Medicine; Eradication
    InterventionBan xia xie xin Decoction and bismuth quadruplicate group; Bismuth quadruplicate group
    PhasePhase 1
    Registry statusUnknown

  • Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection

    NCT05549115 · start 2022-09-20

    Registered record
    Registry ID
    NCT05549115
    Conditions
    Helicobacter Pylori Infection
    Interventions
    clarithromycin-sensitive(first-line); clarithromycin-resistant(first-line); empirical therapy group first-line; levofloxacin-sensitive(rescue treatment); levofloxacin-resistant(rescue treatment); empirical therapy group rescue treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-09-20
    Completion
    2024-02
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionclarithromycin-sensitive(first-line); clarithromycin-resistant(first-line); empirical therapy group first-line; levofloxacin-sensitive(rescue treatment) +2 more
    PhaseNot applicable
    Registry statusUnknown

  • Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

    NCT06823791 · start 2022-08-01

    Registered record
    Registry ID
    NCT06823791
    Conditions
    Helicobacter Pylori Infection; Eradication
    Interventions
    Furazolidone; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2024-07-30
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Eradication
    InterventionFurazolidone; Clarithromycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Vonoprazan Hp Dual or Triple Eradication Regimes

    NCT05345210 · start 2022-04-25

    Registered record
    Registry ID
    NCT05345210
    Conditions
    Helicobacter Pylori
    Interventions
    Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14); Vonoprazan Fumarate+Amoxycillin 14days (VA14); Vonoprazan Fumarate+Amoxycillin 7days (VA7); Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14); Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-04-25
    Completion
    2023-03-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionVonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14); Vonoprazan Fumarate+Amoxycillin 14days (VA14); Vonoprazan Fumarate+Amoxycillin 7days (VA7); Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14) +1 more
    PhasePhase 4
    Registry statusUnknown

  • The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

    NCT05173493 · start 2021-12-30

    Registered record
    Registry ID
    NCT05173493
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin,Furazolidone; Amoxicillin,Levofloxacin; Tetracycline,Furazolidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-30
    Completion
    2023-02-10
    Enrolment
    670

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin,Furazolidone; Amoxicillin,Levofloxacin; Tetracycline,Furazolidone
    PhaseNot recorded
    Registry statusCompleted

  • Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori

    NCT05191875 · start 2021-12-01

    Registered record
    Registry ID
    NCT05191875
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Saccharomyces Boulardii 250 MG; Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2022-04-23
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionSaccharomyces Boulardii 250 MG; Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate
    PhaseNot applicable
    Registry statusCompleted

  • Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin

    NCT05135182 · start 2021-11-28

    Registered record
    Registry ID
    NCT05135182
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Furazolidone; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-11-28
    Completion
    2022-12
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionFurazolidone; Metronidazole
    PhasePhase 4
    Registry statusUnknown